Physician profile
Cory Brown
NPI 1912167818
$8,866.77
in general payments reported to CMS, 2019-2025
26 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $302 · 2021: $3,308 · 2022: $830 · 2023: $1,139 · 2024: $1,235 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,460 · Education: $28.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,459.74 |
| Education | $28.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,788.75 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $1,559.02 | 2019-2025 | Biktarvy |
| Janssen Biotech, INC. | $690.98 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $542.29 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Abbvie INC. | $391.94 | 2022-2025 | Vraylar |
| Janssen Products, LP | $347.80 | 2020-2021 | |
| Novo Nordisk INC | $237.58 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $203.71 | 2025 | Repatha, Otezla |
| Theratechnologies INC. | $171.90 | 2023-2025 | Egrifta, Trogarzo |
| Napo Pharmaceuticals INC | $155.28 | 2019-2024 | Mytesi |
| Dynavax Technologies Corporation | $102.50 | 2022-2024 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $101.46 | 2023 | Symtuza |
| Takeda Pharmaceuticals U.S.A., INC. | $92.40 | 2019-2023 | Trintellix |
| Glaxosmithkline, LLC. | $77.29 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Pfizer INC. | $76.05 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $58.36 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $53.96 | 2019-2023 | Austedo Xr |
| Antares Pharma, INC. | $52.72 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Lilly USA, LLC | $43.52 | 2025 | Mounjaro |
| Inspire Medical Systems, INC. | $25.00 | 2025 | Inspire |
| Oxford Immunotec USA INC | $22.29 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.24 | 2023 | |
| Coopersurgical, INC. | $16.96 | 2023 | Paragard T 380a |
| Cranial Technologies, INC | $15.86 | 2024 | Doc Band |
| Emd Serono, INC. | $12.81 | 2023 | Serostim |
| Organon LLC | $6.10 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.